Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy.

Wiederhold NP, Xu X, Wang A, Najvar LK, Garvey EP, Ottinger EA, Alimardanov A, Cradock J, Behnke M, Hoekstra WJ, Brand SR, Schotzinger RJ, Jaramillo R, Olivo M, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01315-18. doi: 10.1128/AAC.01315-18. Print 2018 Nov.

2.

The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis.

Wiederhold NP, Najvar LK, Garvey EP, Brand SR, Xu X, Ottinger EA, Alimardanov A, Cradock J, Behnke M, Hoekstra WJ, Schotzinger RJ, Jaramillo R, Olivo M, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01071-18. doi: 10.1128/AAC.01071-18. Print 2018 Sep.

3.

Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy.

Xu X, Wang AQ, Latham LL, Celeste F, Ciccone C, Malicdan MC, Goldspiel B, Terse P, Cradock J, Yang N, Yorke S, McKew JC, Gahl WA, Huizing M, Carrillo N.

Mol Genet Metab. 2017 Sep;122(1-2):126-134. doi: 10.1016/j.ymgme.2017.04.010. Epub 2017 Apr 26.

4.

Diphtheria Toxin- and GFP-Based Mouse Models of Acquired Hypoparathyroidism and Treatment With a Long-Acting Parathyroid Hormone Analog.

Bi R, Fan Y, Lauter K, Hu J, Watanabe T, Cradock J, Yuan Q, Gardella T, Mannstadt M.

J Bone Miner Res. 2016 May;31(5):975-84. doi: 10.1002/jbmr.2769. Epub 2016 Jan 20.

5.

Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease.

Ottinger EA, Kao ML, Carrillo-Carrasco N, Yanjanin N, Shankar RK, Janssen M, Brewster M, Scott I, Xu X, Cradock J, Terse P, Dehdashti SJ, Marugan J, Zheng W, Portilla L, Hubbs A, Pavan WJ, Heiss J, Vite CH, Walkley SU, Ory DS, Silber SA, Porter FD, Austin CP, McKew JC.

Curr Top Med Chem. 2014;14(3):330-9. Review.

6.

Evaluating client and family preferences regarding outcomes in severe mental illness.

Cradock JA, Young AS, Forquer SL.

Adm Policy Ment Health. 2002 Jan;29(3):257-61. No abstract available.

PMID:
12033670
7.

The accuracy of medical record documentation in schizophrenia.

Cradock J, Young AS, Sullivan G.

J Behav Health Serv Res. 2001 Nov;28(4):456-65.

PMID:
11732247
8.

Computer-assisted structure-activity correlations of halodideoxynucleoside analogs as potential anti-HIV drugs.

Nasr M, Cradock J, Johnston MI.

AIDS Res Hum Retroviruses. 1992 Feb;8(2):135-44.

PMID:
1540402
9.

Overview of the preclinical development of an antiretroviral drug, 2',3'-dideoxyinosine.

McGowan JJ, Tomaszewski JE, Cradock J, Hoth D, Grieshaber CK, Broder S, Mitsuya H.

Rev Infect Dis. 1990 Jul-Aug;12 Suppl 5:S513-20; discussion S520-1. Review.

PMID:
2117302
10.

Oligodeoxynucleotides as anti-sense inhibitors of gene expression: therapeutic implications.

Rothenberg M, Johnson G, Laughlin C, Green I, Cradock J, Sarver N, Cohen JS.

J Natl Cancer Inst. 1989 Oct 18;81(20):1539-44. Review. No abstract available.

PMID:
2677394
11.

Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials.

Grem JL, Shoemaker DD, Hoth DF, King SA, Plowman J, Zaharko D, Grieshaber CK, Harrison SD Jr, Cradock JC, Leyland-Jones B.

Invest New Drugs. 1987 Dec;5(4):315-28. Review.

PMID:
2449402
12.

Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.

Cheung YW, Cradock JC, Vishnuvajjala BR, Flora KP.

Am J Hosp Pharm. 1987 Jan;44(1):124-30.

PMID:
3548341
13.

Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.

O'Dwyer PJ, Shoemaker D, Zaharko DS, Grieshaber C, Plowman J, Corbett T, Valeriote F, King SA, Cradock J, Hoth DF, et al.

Cancer Chemother Pharmacol. 1987;19(1):6-10. Review.

PMID:
3545524
14.

Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors.

Zaharko DS, Grieshaber CK, Plowman J, Cradock JC.

Cancer Treat Rep. 1986 Dec;70(12):1415-21.

PMID:
3791254
15.

Hexamethylene bisacetamide: a polar-planar compound entering clinical trials as a differentiating agent.

Chun HG, Leyland-Jones B, Hoth D, Shoemaker D, Wolpert-DeFilippes M, Grieshaber C, Cradock J, Davignon P, Moon R, Rifkind R, et al.

Cancer Treat Rep. 1986 Aug;70(8):991-6. Review. No abstract available.

PMID:
3524838
16.
17.

Uridine-induced hyperthermia in the rabbit.

Cradock JC, Vishnuvajjala BR, Chin TF, Hochstein HD, Ackerman SK.

J Pharm Pharmacol. 1986 Mar;38(3):226-9.

PMID:
2871163
18.

Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey.

Perlin E, Smith CG, Nichols AI, Almirez R, Flora KP, Cradock JC, Peck CC.

J Pharm Sci. 1985 Feb;74(2):171-4.

PMID:
2985774
19.

Trimetrexate: a new antifol entering clinical trials.

O'Dwyer PJ, Shoemaker DD, Plowman J, Cradock J, Grillo-Lopez A, Leyland-Jones B.

Invest New Drugs. 1985;3(1):71-5.

PMID:
3157662
20.

Stability of melphalan in infusion fluids.

Tabibi SE, Cradock JC.

Am J Hosp Pharm. 1984 Jul;41(7):1380-2. No abstract available.

PMID:
6465155
21.

Compatibility of plastic infusion devices with diluted N-methylformamide and N,N-dimethylacetamide.

Vishnuvajjala BR, Cradock JC.

Am J Hosp Pharm. 1984 Jun;41(6):1160-3.

PMID:
6741960
22.

Menogaril: a new anthracycline agent entering clinical trials.

McGovren JP, Nelson KG, Lassus M, Cradock JC, Plowman J, Christopher JP.

Invest New Drugs. 1984;2(4):359-67.

PMID:
6239835
23.

The hydrolysis of spirohydantoin mustard.

Flora KP, Cradock JC, Kelley JA.

J Pharm Sci. 1982 Nov;71(11):1206-11.

PMID:
7175709
24.

Determination of ellipticine in biological samples by high-performance liquid chromatography.

Bykadi G, Flora KP, Cradock JC, Poochikian GK.

J Chromatogr. 1982 Aug 13;231(1):137-44.

PMID:
7119056
25.

Stability of anthracycline antitumor agents in four infusion fluids.

Poochikian GK, Cradock JC, Flora KP.

Am J Hosp Pharm. 1981 Apr;38(4):483-6.

PMID:
6945043
26.

Determination of delta 9-tetrahydrocannabinol in pharmaceutical vehicles by high-performance liquid chromatography.

Flora KP, Cradock JC, Davignon JP.

J Chromatogr. 1981 Feb 6;206(1):117-23.

PMID:
6260828
28.

Morphine acetate.

Poochikian GK, Cradock JC, Davignon JP.

JAMA. 1980 Sep 26;244(13):1434. No abstract available.

PMID:
7420622
29.

The loss of paraben preservatives during freeze drying.

Flora KP, Cradock JC, Poochikian GK.

J Pharm Pharmacol. 1980 Aug;32(8):577-8. No abstract available.

PMID:
6106697
30.
31.

Low temperature vacuum drying: evaluation of excipients in injectable dosage forms.

Flora KP, Rahman A, Cradock JC.

J Parenter Drug Assoc. 1980 May-Jun;34(3):192-9. No abstract available.

PMID:
6901775
33.

Enhanced chartreusin solubility by hydroxybenzoate hydrotropy.

Poochikian GK, Cradock JC.

J Pharm Sci. 1979 Jun;68(6):728-32.

PMID:
458574
35.

Dissolution and absorption of the antineoplastic agent ellipticine.

Rahman A, Cradock JC, Davignon JP.

J Pharm Sci. 1978 May;67(5):611-4.

PMID:
641792
36.

A simple method for the estimation of amygdalin in the urine.

Flora KP, Cradock JC, Ames MM.

Res Commun Chem Pathol Pharmacol. 1978 May;20(2):367-78.

PMID:
566946
37.
38.

Reduction of pyrogens--application of molecular filtration.

Cradock JC, Guder LA, Francis DL, Morgan SL.

J Pharm Pharmacol. 1978 Mar;30(3):198-9. No abstract available.

PMID:
24702
39.

Intrathecal injections--a review of pharmaceutical factors.

Cradock JC, Kleinman LM, Davignon JP.

Bull Parenter Drug Assoc. 1977 Sep-Oct;31(5):237-47. Review. No abstract available.

PMID:
21718
40.

Formulation of three nitrosoureas for intravenous use.

Davignon JP, Yang KW, Wood HB Jr, Cradock JC.

Cancer Chemother Rep 3. 1973 May;4(3):7-11. No abstract available.

PMID:
4201309
41.

An intravenous formulation of 9-tetrahydrocannabinol using a non-ionic surfactant.

Cradock JC, Davignon JP, Litterst CL, Guarino AM.

J Pharm Pharmacol. 1973 Apr;25(4):345. No abstract available.

PMID:
4146694
42.

Daunorubicin biliary excretion and metabolism in the rat.

Cradock JC, Egorin MJ, Bachur NR.

Arch Int Pharmacodyn Ther. 1973 Mar;202(1):48-61. No abstract available.

PMID:
4694357
43.

A computer-based medication system for cancer chemotherapy patients.

Goldman G, Fortner CL, Cradock J, Murray B, Hsieh R, Thompson WL, Block JB.

Am J Hosp Pharm. 1972 Apr;29(4):305-11. No abstract available.

PMID:
5025260
44.

Postadmission drug and allergy histories recorded by a pharmacist.

Cradock JC, Whitfield GR, Menzie JW, Fortner CL.

Am J Hosp Pharm. 1972 Mar;29(3):250-2. No abstract available.

PMID:
5028479
45.

A unit dose system for handling parenteral investigational cancer chemotherapeutic agents.

Menzie JW, Fortner CL, Cradock JC.

Am J Hosp Pharm. 1971 Aug;28(8):605-10. No abstract available.

PMID:
5092589
46.

Reduction in serum CO2 content during hyperalimentation therapy.

Fortner CL, Foley T, Cradock JC.

Am J Hosp Pharm. 1971 Feb;28(2):121-2. No abstract available.

PMID:
4994661
47.

Daunomycin metabolism in rat tissue slices.

Bachur NR, Cradock JC.

J Pharmacol Exp Ther. 1970 Nov;175(2):331-7. No abstract available.

PMID:
5481703

Supplemental Content

Loading ...
Support Center